A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Minimally Invasive Treatment Could Allow More Women to Conceive Without Fertility Treatments: Society for Interventional Radiology

Simple diagnostic procedure and treatment can provide clarity on infertility and hope for conception

A simple diagnostic procedure, followed by an interventional radiology treatment known as fallopian tube recanalization, could allow a high percentage of women struggling with infertility from blocked fallopian tubes to conceive with less involved or, in some cases, no further invasive fertility procedures, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting. Researchers said that most women with with blocked fallopian tubes could have their condition easily corrected.

“This procedure and treatment can help women make an informed decision about infertility treatments. And for many, it can actually give them the chance to conceive naturally,” said Lindsay Machan, MD, associate professor in the Department of Radiology at the University of British Columbia and a lead author of the study. “As women increasingly desire more thorough discussions of available options and input into their medical care, they appreciate detailed information to help them make choices. This is especially true with fertility treatments.”

Researchers at the University of British Columbia Hospital studied cases from 2015 to 2021 involving 956 women with infertility who previously had been diagnosed as having one or both fallopian tubes blocked based on the standard diagnostic procedure used to assess the openness of fallopian tubes, known as hysterosalpingogram (HSG).  The women then underwent a selective salpingography to confirm their HSG diagnosis and, if needed, underwent fallopian tube recanalization. In many cases, researchers said, the purported blockage was only a piece of mucus that was easily removed.

The diagnostic examination known as selective salpingography showed that nearly one in four (23.8%) had been mistakenly told they had one or both blocked fallopian tubes.  Of those with a blockage, over half (56.7%) were unblocked using a fine wire in the fallopian recanalization process, researchers said. In sum, 80.5% of women in the study who had previously been told they had tubal blockages left the same day with both fallopian tubes open after a simple outpatient procedure. In an additional 15.9% a more precise diagnosis of significant tubal disease was made that in many cases, potentially altered treatment options.

Selective salpingography uses X-ray guidance to insert a tiny catheter through the cervix and into the opening of the fallopian tubes. A contrast dye is then injected to assess whether the tubes are open or blocked. The interventional radiologist, in many cases, is then able to perform recanalization which opens the tube using a fine guidewire. The procedure is performed as an outpatient under light sedation and typically takes under 30 minutes.

Machan said the research suggests that selective salpingography should be offered more broadly in assessing and treating female infertility. “Fertility treatments can be expensive and out of reach for many women,” he said. “Infertility is also an emotional, often heart-breaking journey, so having this diagnostic procedure and treatment available could be life-changing.”

Abstract 135: Radiologic Findings in Infertile Women Referred for Selective Salpingography and Fallopian Tube Recanalization. A. Sharma, A. Hadjivassiliou, L. Machan. Annual Scientific Meeting, June 11-16, 2022. This abstract can be found at sirmeeting.org after the embargo time.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy